Investors

Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases

  • April 3, 2014 at 12:00 AM EDT
    Combining with cyclophosphamide and the checkpoint inhibitor anti-PD-1 enhances the therapeutic potential of vaccine Halifax, Nova Scotia; April 3, 201 4 – Immunovaccine Inc. (“Immunovaccine” or “IMV”) (TSX-V: IMV), a clinical stage vaccine company, today announced that data from clinical and
  • April 1, 2014 at 12:00 AM EDT
    Data demonstrates 100% protection against a lethal anthrax challenge in animals after vaccination with as little as 0.33 microgram of mutant recombinant Protective Antigen; Dose response observed in the first 28 days following vaccination HALIFAX, NOVA SCOTIA and SAN DIEGO, CALIFORNIA - April 1,
  • March 17, 2014 at 12:00 AM EDT
    Halifax, Nova Scotia; March 17, 2014 – Immunovaccine Inc. (TSX-V: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013. “During 2013, scientists provided compelling evidence that the human immune system could be trained
  • January 20, 2014 at 12:00 AM EST
    Halifax, Nova Scotia; January 20, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today announced that pursuant to terms and conditions of the Company's stock option plan, it has granted 1,731,500 stock options
  • January 20, 2014 at 12:00 AM EST
    Halifax, Nova Scotia; January 20, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.   Dr.
  • January 9, 2014 at 12:00 AM EST
    Halifax, Nova Scotia; January 9, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at the 6th Annual Biotech Showcase Conference.
  • December 16, 2013 at 12:00 AM EST
    Halifax, Nova Scotia; December 16, 2013 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today announced the election of Marc Mansour, Ph.D., the Company’s Chief Operating Officer (COO), to its board of directors.
  • November 29, 2013 at 12:00 AM EST
    Halifax, Nova Scotia ; November 29, 2013 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today released its financial and operational results for the quarter ended September 30, 2013.
  • November 21, 2013 at 12:00 AM EST
    Halifax, Nova Scotia; November 21, 2013 – Immunovaccine Inc. (“Immunovaccine” or “IMV”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, has closed the previously announced private placement of its securities, raising gross proceeds of $4.2 million (the “ Private Placement ”).
  • October 28, 2013 at 12:00 AM EDT
    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. Halifax, Nova Scotia, October 28, 2013 – Immunovaccine Inc.